Clinical Trials Logo

Nasopharyngeal Cancer clinical trials

View clinical trials related to Nasopharyngeal Cancer.

Filter by:

NCT ID: NCT02012699 Recruiting - Breast Cancer Clinical Trials

Integrated Cancer Repository for Cancer Research

iCaRe2
Start date: November 1, 2013
Phase:
Study type: Observational [Patient Registry]

The iCaRe2 is a multi-institutional resource created and maintained by the Fred & Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.

NCT ID: NCT01312311 Recruiting - Clinical trials for Nasopharyngeal Cancer

Weekly Docetaxel Plus Cisplatin as the First-line Therapy for Nasopharyngeal Cancer

Start date: July 2006
Phase: Phase 2
Study type: Interventional

The investigators will evaluate weekly docetaxel plus 3-weekly cisplatin regimen as the first-line therapy for recurrent of metastatic nasophayngeal cancer

NCT ID: NCT00304694 Recruiting - Clinical trials for Nasopharyngeal Cancer

Whole-Body 18F-FDG PET in Induction Chemotherapeutic Response for Advanced NPC Patients

Start date: March 2006
Phase: N/A
Study type: Observational

18F-FDG PET, a whole-body imaging technology based on glucose metabolism, can effectively detect subclinical and clinical therapeutic responses at stages that are earlier than those detected by conventional approaches. We propose to conduct a prospective study to evaluate therapeutic response using 18F-FDG PET before and after induction chemotherapy for locally advanced NPC patients.